Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 7/20 | 0.78 |
| ▸ | DRD2 | P14416 | 3/20 | 0.78 |
| ▸ | MAPT | P10636 | 2/20 | 0.78 |
| ▸ | TLR4 | O00206 | 2/20 | 0.78 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.78 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.78 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.78 |
| ▸ | MLNR | O43193 | 1/20 | 0.78 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.78 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.78 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.78 |
| ▸ | APP | P05067 | 1/20 | 0.78 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.78 |
| ▸ | HTR1A | P08908 | 1/20 | 0.78 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.78 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.78 |
| ▸ | GAA | P10253 | 1/20 | 0.78 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.78 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7410044 | 0.93 | ADRB2 (0.67) | ADRB2DRD2MAPTTLR4ADRB1 | |
| SCHEMBL7411219 | 0.92 | ADRB2 (0.66) | ADRB2DRD2MAPTTLR4ADRB1 | |
| SCHEMBL7412337 | 0.92 | ADRB2 (0.66) | ADRB2DRD2MAPTTLR4ADRB1 | |
| SCHEMBL7403484 | 0.90 | ADRB2 (0.63) | ADRB2DRD2MAPTTLR4ADRB1 | |
| SCHEMBL7410118 | 0.90 | ADRB2 (0.63) | ADRB2DRD2MAPTTLR4ADRB1 | |
| Carvedilol SCHEMBL5465072 | 0.89 | ADRB2 (0.98) | ADRB2DRD2MAPTTLR4ADRB1 | |
| SCHEMBL7417184 | 0.88 | ADRB2 (0.61) | ADRB2DRD2MAPTTLR4ADRB1 | |
| SCHEMBL7410154 | 0.88 | ADRB2 (0.61) | ADRB2DRD2MAPTTLR4ADRB1 | |
| SCHEMBL7410183 | 0.88 | ADRB2 (0.61) | ADRB2DRD2MAPTTLR4ADRB1 | |
| SCHEMBL7407193 | 0.88 | ADRB2 (0.61) | ADRB2DRD2MAPTTLR4ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160214973-A1 | STORE OVERLOAD-INDUCED CALCIUM RELEASE INHIBITORS AND METHODS FOR PRODUCING AND USING THE SAME | UTI LIMITED PARTNERSHIP (CA) | 2016-07-28 | — | — | US | disclosed |
| WO-2015031914-A1 | STORE OVERLOAD-INDUCED CALCIUM RELEASE INHIBITORS AND METHODS FOR PRODUCING AND USING THE SAME | UTI LIMITED PARTNERSHIP (CA) | 2015-03-05 | — | — | WO | disclosed |
| WO-2009116069-A2 | PROCESS FOR PREPARATION OF 1-(9H-CARBAZOL-4-YLOXY)-3-[[2-(2- METHOXYPHENOXY) ETHYL] AMINO]-2-PROPANOL | IPCA LABORATORIES LIMITED (IN) | 2009-09-24 | — | — | WO | disclosed |
| US-20090176992-A1 | PROCESS FOR THE PREPARATION OF HIGHLY OPTICAL PURE CARVEDILOL | RSTECH CORPORATION (KR) | 2009-07-09 | — | — | US | disclosed |
| US-20090176992-A1 | PROCESS FOR THE PREPARATION OF HIGHLY OPTICAL PURE CARVEDILOL | RSTECH CORPORATION (KR) | 2009-07-09 | — | — | US | disclosed |
| WO-2007097504-A1 | PROCESS FOR THE PREPARATION OF HIGHLY OPTICAL PURE CARVEDILOL | AHN-GOOK PHARMACEUTICAL CO., LTD. (KR) | 2007-08-30 | — | — | WO | disclosed |
| EP-1660451-A2 | NEW CRYSTALLINE FORMS OF CARVEDILOL | KRKA, tovarna zdravil, d.d., Novo mesto (SI) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005021504-A2 | NEW CRYSTALLINE FORMS OF CARVEDILOL | KRKA, TOVARNA ZDRAVIL, D.D., NOVO MESTO (SI) | 2005-03-10 | — | — | WO | disclosed |
| EP-1098646-B1 | STABILIZED CARVEDILOL INJECTION SOLUTION | ROCHE DIAGNOSTICS GMBH (DE) | 2004-09-22 | — | — | EP | disclosed |
| EP-1098646-A1 | STABILIZED CARVEDILOL INJECTION SOLUTION | Roche Diagnostics GmbH (DE) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000004902-A1 | STABILIZED CARVEDILOL INJECTION SOLUTION | ROCHE DIAGNOSTICS GMBH (DE) | 2000-02-03 | — | — | WO | disclosed |
| US-4503067-A | HYPOTENSIVE, ANGINA PECTORIS | BOEHRINGER MANNHEIM GMBH (DE) | 1985-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214973-A1 | STORE OVERLOAD-INDUCED CALCIUM RELEASE INHIBITORS AND METHODS FOR PRODUCING AND USING THE SAME | ORAI1, RYR2, CASR | ADRB2 751/4885DRD2 3630/4885MAPT 4171/4885 |
| US-20090176992-A1 | PROCESS FOR THE PREPARATION OF HIGHLY OPTICAL PURE CARVEDILOL | ADRB2, ADRB1, ADRB3 | ADRB2 1/4885DRD2 324/4885MAPT 3119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.